DOES TRANSENDOCARDIAL INJECTION OF MESENCHYMAL STEM CELLS IMPROVE MYOCARDIAL FUNCTION LOCALLY, OR GLOBALLY: AN ANALYSIS FROM THE POSEIDON TRIAL

Viky Y. Suncion,Eduard Ghersin,Juan P. Zambrano,Vasileios Karantalis,Nicole Mandel,Katarina H. Nelson,Joel E. Fishman,Gary Gerstenblith,Darcy L. Velazquez,Elayne Breton,Ivonne Hernandez Schulman,Kranthi Sitammagari,Peter V. Johnston,Jeffrey A. Brinker,Peter A. Altman,Muzammil Mushtaq,Barry Trachtenberg,Jose Da Silva,Ian McNiece,Albert C. Lardo,Richard T. George,Joshua M. Hare,Alan W. Heldman

DOES TRANSENDOCARDIAL INJECTION OF MESENCHYMAL STEM CELLS IMPROVE MYOCARDIAL FUNCTION LOCALLY, OR GLOBALLY: AN ANALYSIS FROM THE POSEIDON TRIAL

2013

Transendocardial Stem Cell Injection (TESI) with mesenchymal stem cells improves left ventricular (LV) geometry in chronic ischemic cardiomyopathy, by reducing myocardial scar, LV volumes, and sphericity index. To address whether TESI exerts its effects at the site of injection only or also in

Keywords:

Mesenchymal stem cell
Cardiology
Medicine
Internal medicine
myocardial function
Diabetes mellitus
Stem cell
Ischemic cardiomyopathy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations